Additional data from pivotal METEOR trial underscore clinically meaningful benefit of Exelixis’ (EXEL) drug Cabometyx™ for patients with Advanced RCC
AT the ASCO Meeting: ABSTRACT #4557, #4558
Cabometyx’™ benefit was robust and consistent regardless of prior treatment, location and extent of tumor metastases
Positive data will be presented at the 2016 American Society of Clinical Oncology (ASCO) from subgroup analyses of the pivotal METEOR trial. The data are from trial compared Ccbometyx™ (cabozantinib) tablets with everolimus in 658 patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy . . .
This content is for paid subscribers.
Today’s Highlights June 6, 2016